185 related articles for article (PubMed ID: 36806098)
1. Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population-based cohort study.
Lee JW; Heo YW; Lee JH; Lee S
J Dermatol; 2023 Jun; 50(6):778-786. PubMed ID: 36806098
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.
Lee JH; Kwon HS; Jung HM; Kim GM; Bae JM
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1784-1790. PubMed ID: 29761904
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of cardiovascular comorbidities in hidradenitis suppurativa: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Chiang CP; Chung CH; Tsao CH; Chien WC; Wang WM
J Dermatol; 2019 Oct; 46(10):867-873. PubMed ID: 31389066
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa.
Jung JM; Lee KH; Kim YJ; Chang SE; Lee MW; Choi JH; Won CH; Lee WJ
JAMA Dermatol; 2020 Aug; 156(8):844-853. PubMed ID: 32459291
[TBL] [Abstract][Full Text] [Related]
5. Demographic and clinical features of hidradenitis suppurativa in Korea.
Yang JH; Moon J; Kye YC; Kim KJ; Kim MN; Ro YS; Park MY; Ahn HH; Lee MW; Lee WJ; Lee JH; Lee JB; Jang MS; Choi YS; Choi YW; Suh DH;
J Dermatol; 2018 Dec; 45(12):1389-1395. PubMed ID: 30294846
[TBL] [Abstract][Full Text] [Related]
6. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.
Shlyankevich J; Chen AJ; Kim GE; Kimball AB
J Am Acad Dermatol; 2014 Dec; 71(6):1144-50. PubMed ID: 25440440
[TBL] [Abstract][Full Text] [Related]
7. All-Cause and Cause-Specific Mortality Risks among Patients with Hidradenitis Suppurativa: A Korean Nationwide Population-Based Cohort Study.
Lee S; Lee JY; Han JH; Ju HJ; Lim SH; Bae JM; Lee JH
J Invest Dermatol; 2023 Jun; 143(6):944-953.e8. PubMed ID: 36566877
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of hidradenitis suppurativa in Taiwan: A 14-year nationwide population-based study.
Liang YT; Yeh CJ; Huang JY; Wei JC
J Dermatol; 2021 May; 48(5):613-619. PubMed ID: 33626195
[TBL] [Abstract][Full Text] [Related]
9. Risk of Chronic Kidney Disease in Hospitalized Patients with Hidradenitis Suppurativa.
Almuhanna N; Tobe SW; Alhusayen R
Dermatology; 2023; 239(6):912-918. PubMed ID: 37487485
[TBL] [Abstract][Full Text] [Related]
10. Association of metabolic syndrome and hidradenitis suppurativa.
Miller IM; Ellervik C; Vinding GR; Zarchi K; Ibler KS; Knudsen KM; Jemec GB
JAMA Dermatol; 2014 Dec; 150(12):1273-80. PubMed ID: 25229996
[TBL] [Abstract][Full Text] [Related]
11. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Garg A; Malviya N; Strunk A; Wright S; Alavi A; Alhusayen R; Alikhan A; Daveluy SD; Delorme I; Goldfarb N; Gulliver W; Hamzavi I; Jaleel T; Kimball AB; Kirby JS; Kirchhof MG; Lester J; Lev-Tov H; Lowes MA; Micheletti R; Orenstein LA; Piguet V; Sayed C; Tan J; Naik HB
J Am Acad Dermatol; 2022 May; 86(5):1092-1101. PubMed ID: 33493574
[TBL] [Abstract][Full Text] [Related]
12. Somatic and psychiatric comorbidities of hidradenitis suppurativa in children and adolescents.
Tiri H; Jokelainen J; Timonen M; Tasanen K; Huilaja L
J Am Acad Dermatol; 2018 Sep; 79(3):514-519. PubMed ID: 29518461
[TBL] [Abstract][Full Text] [Related]
13. Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.
Pinter A; Kokolakis G; Rech J; Biermann MHC; Häberle BM; Multmeier J; Reinhardt M
Dermatol Ther (Heidelb); 2020 Aug; 10(4):721-734. PubMed ID: 32500484
[TBL] [Abstract][Full Text] [Related]
14. Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis.
Gau SY; Preclaro IAC; Wei JC; Lee CY; Kuan YH; Hsiao YP; Juang SE; Ma KS
Front Immunol; 2022; 13():1033844. PubMed ID: 36532043
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the management of comorbidity in hidradenitis suppurativa.
Dauden E; Lazaro P; Aguilar MD; Blasco AJ; Suarez C; Marin I; Queiro R; Bassas-Vila J; Martorell A; García-Campayo J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):129-144. PubMed ID: 28796920
[TBL] [Abstract][Full Text] [Related]
16. Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large-scale, propensity-matched global retrospective cohort study.
Krajewski PK; Matusiak Ł; Ständer S; Thaçi D; Szepietowski JC; Zirpel H
Int J Dermatol; 2024 Jun; 63(6):799-805. PubMed ID: 38644522
[TBL] [Abstract][Full Text] [Related]
17. Association between hidradenitis suppurativa and atopic diseases: a multi-center, propensity-score-matched cohort study.
Chang HC; Lin CY; Guo YC; Lu HY; Lee CY; Wu MC; Gau SY
Int J Med Sci; 2024; 21(2):299-305. PubMed ID: 38169580
[No Abstract] [Full Text] [Related]
18. Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study.
Tzur Bitan D; Berzin D; Cohen A
Dermatology; 2020; 236(4):298-304. PubMed ID: 31910425
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, Risk Factors, and Comorbidities of Hidradenitis Suppurativa.
Miller IM; McAndrew RJ; Hamzavi I
Dermatol Clin; 2016 Jan; 34(1):7-16. PubMed ID: 26617352
[TBL] [Abstract][Full Text] [Related]
20. The in-hospital burden of hidradenitis suppurativa in patients with inflammatory bowel disease: a decade nationwide analysis from 2004 to 2014.
Ramos-Rodriguez AJ; Timerman D; Khan A; Bonomo L; Hunjan MK; Lemor A
Int J Dermatol; 2018 May; 57(5):547-552. PubMed ID: 29431201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
